Er Stress Research Institute Inc. has disclosed benzothiazoimidazolyl compounds acting as endoplasmic reticulum (ER) stress inhibitors reported to be useful for the treatment of cancer, diabetes, neurodegenerative, autoimmune and metabolic diseases as well as renal, cardiovascular and renal disorders.